Skip to main content
. 2022 Jan 17;11(2):471. doi: 10.3390/jcm11020471

Table 1.

Sociodemographic and clinical characteristics of PLHIV according with level of disease and treatment burden.

Characteristics L-TBD
(n = 432; 81.3%)
H-TDB
(n = 99; 18.6%)
p-Value Total
Age, years, median (IQR) 50 (41–57) 44 (34–53) <0.001 49 (39–56)
Sex *, Male, n (%) 375 (86.8) 87 (87.9) 0.775 462 (87.0)
Education, n (%) 0.109
Middle/High School 254 (58.8) 50 (50.5) 304 (57.2)
University/Master 176 (40.7) 47 (47.5) 223 (42.0)
Other/Unknown 2 (0.5) 2 (2.0) 4 (0.7)
Job, n (%) 0.102
Stable work 272 (62.9) 52 (52.5) 324 (60.0)
Not stable work 55 (12.7) 15 (15.1) 70 (13.2)
Not working 44 (10.2) 18 (18.2) 62 (11.7)
Other/Unknown/Retired 61 (14.1) 14 (14.1) 75 (14.1)
Italy Born, n (%) 406 (94.0) 92 (92.9) 0.696 498 (93.8)
Year HIV Diagnosis, n (%) 0.178
<2001 106 (24.5) 23 (23.2) 129 (24.3)
2001–2010 114 (26.4) 18 (18.2) 132 (24.9)
2011–2015 108 (25) 25 (25.2) 133 (25)
>2015 104 (24.1) 33 (33.3) 137 (25.8)
Year first ARV start, n (%) 0.137
<2001 89 (20.6) 17 (17.17) 106 (19.9)
2001–2010 109 (25.23) 17 (17.17) 126 (23.7)
2011–2015 116 (26.85) 28 (28.28) 144 (27.1)
>2015 118 (27.31) 37 (37.37) 155 (29.2)
Mode of HIV
transmission, n (%)
0.194
Homosexual Contacts 274 (63.4) 52 (52.5) 326 (61.4)
Heterosexual Contacts 31 (7.2) 7 (7.1) 38 (7.2)
Sexual contacts (mode not specified) 88 (20.4) 27 (27.3) 115 (21.7)
Other not-sexual mode 39 (9.0) 13 (13.1) 52 (9.8)
Current HIV-RNA,
copies/mL, n (%)
0.044
<50 copiess/mL 388 (89.8) 80 (80.8) 468 (88.1)
≥50 copies/mL 19 (4.4) 8 (8.1) 27 (5.1)
unknown/not reported 25 (5.8) 11 (11.1) 36 (6.8)
Current CD4, cells/mmc, n (%) 0.463
<200 cells/mmc 39 (9.0) 12 (12.12) 51 (9.6)
200–500 cells/mmc 87 (20.14) 18 (18.18) 105 (19.8)
>500 cells/mmc 251 (58.1) 52 (52.53) 303 (57.1)
unknown/not reported 55 (12.73) 17 (17.17) 72 (13.6)
Current Regimen (R), n (%) 0.011
2 ARV R STR 85 (19.68) 13 (13.13) 98 (18.46)
3 ARV R STR (w/o booster) 203 (46.99) 46 (46.46) 249 (46.9)
3 ARV R STR (with booster) 32 (7.41) 14 (14.14) 46 (8.66)
2 ARV R MTR 58 (13.43) 8 (8.08) 66 (12.4)
3 ARV R MTR 37 (8.56) 7 (7.07) 44 (8.3)
Unknown 17 (3.9) 11 (11.1) 28 (5.3)
STR, n (%) 320 (77.1) 73 (82.9) 0.228 393 (78.1)
Treatment Satisfaction, n (%) 0.007
Yes, fully 243 (56.25) 26 (26.26) 269 (50.66)
Yes, but can be improved 180 (41.67) 61 (61.62) 241 (45.39)
No, I’ve some issues 9 (2.08) 7 (7.07) 16 (3.01)
Not at all 0 (0.0) 2 (2.02) 2 (0.38)
Other/Unknown 0 (0.0) 3 (3.0) 3 (0.6)
Number of daily assumption of all the drugs > 1, n (%) 106 (24.5) 26 (26.3) 0.72 132 (24.9)
Polypharmacy, ≥5 drugs/day, n (%) 75 (17.4) 18 (18.2) 0.846 93 (17.5)
Physical Health, (1–5 scale), median (IQR) 2 (1–3) 3 (2–3) <0.001 2 (1–3)
Mental Health, (1–5 scale), median (IQR) 2 (1–3) 3 (2–4) <0.001 2 (2–3)
Sexual Health, (1–5 scale), median (IQR) 3 (2–4) 4 (3–5) <0.001 3 (3–5)
Overall Health, (1–5 scale), median (IQR) 2 (2–3) 3 (2–3) <0.001 2 (2–3)

Abbreviations: 2 ARV R (2-drug antiretroviral regimen), 3 ARV R (3-drug antiretroviral regimen), STR (single tablet regimen), MTR (multiple tablet regimen), w/o (without). * Sex at birth.